Dosage Reduction and Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramadan

• Status: Completed
• Trial end date: 2017-07-24
• Target enrollment: 0
• Participant gender: All

Summary

Every lunar year, during the month of Ramadan, Muslims abstain from food and drink between dawn and nightfall. People with type 2 diabetes who fast during Ramadan are at an increased risk of acute glycemic complications. Our aim is to investigate the effect of dosage reduction of four glucose-lowering multidrug regimens on the incidence of acute glycemic complications in people with type 2 diabetes who fast during Ramadan.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Jordan
• Treatments: Glimepiride; Insulin; Insulin Glargine; Insulin, Globin Zinc; Metformin; Vildagliptin

Criteria

Inclusion Criteria:

• Prospective participant is a returning patient with type 2 diabetes;

• Prospective participant expressed an intention to fast during Ramadan;

• Prospective participant has been compliant with one of four glucose-lowering multidrug regimens for at least the past three months.

Exclusion Criteria:

• Prospective participant is a pregnant, postpartum, breastfeeding, or eumenorrheic woman;

• Prospective participant has experienced diabetic ketoacidosis or hyperosmolar hyperglycemic state within three months;

• Prospective participant has received niacin or corticosteroids within one month; and,

• Prospective participant has any history of recurrent hypoglycemia, hypoglycemia unawareness, chronic renal insufficiency (stages IV or V), liver cirrhosis, uncontrolled epilepsy, depressive disorder, bipolar disorder, psychotic disorder, or cognitive dysfunction.